Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 11 (November)

1. The impact of margin status on local recurrence following breast conserving therapy for invasive carcinoma in Manitoba.
   J Surg Oncol, 98(6): 399-402. [Abstract] [Full-text]
2. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer.
   J Surg Oncol, 98(6): 403-6. [Abstract] [Full-text]
3. ERp29, an endoplasmic reticulum secretion factor is involved in the growth of breast tumor xenografts.
   Mol Carcinog, 47(11): 886-92. [Abstract] [Full-text]
4. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
   Mol Carcinog, 47(11): 845-85. [Abstract] [Full-text]
5. Anaplastic large-cell lymphoma in women with breast implants.
   JAMA, 300(17): 2030-5. [Abstract] [Full-text]
6. Refinement and psychometric evaluation of the impact of cancer scale.
   J Natl Cancer Inst, 100(21): 1530-41. [Abstract] [Full-text]
7. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
   J Natl Cancer Inst, 100(21): 1519-29. [Abstract] [Full-text]
8. Risk of breast cancer associated with papilloma.
   Eur J Surg Oncol, 34(12): 1304-8. [Abstract] [Full-text]
9. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature.
   Eur J Surg Oncol, 34(12): 1277-84. [Abstract] [Full-text]
10. Intraoperative ultrasound is an effective and preferable technique to localize non-palpable breast tumors.
    Eur J Surg Oncol, 34(12): 1289-92. [Abstract] [Full-text]
11. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
    Eur J Surg Oncol, 34(12): 1299-303. [Abstract] [Full-text]
12. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
    Biochem Biophys Res Commun, 377(1): 242-7. [Abstract] [Full-text]
13. Improved synthesis of 6-epi-dictyostatin and antitumor efficacy in mice bearing MDA-MB231 human breast cancer xenografts.
    J Med Chem, 51(21): 6650-3. [Abstract] [Full-text]
14. Tamoxifen use and osteoporotic fracture risk: a population-based analysis.
    J Clin Oncol, 26(32): 5227-32. [Abstract] [Full-text]
15. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.
    J Clin Oncol, 26(32): 5213-9. [Abstract] [Full-text]
16. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors.
    J Clin Oncol, 26(32): 5220-6. [Abstract] [Full-text]
17. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
    J Clin Oncol, 26(32): 5269-74. [Abstract] [Full-text]
18. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.
    Cancer, 113(10): 2627-37. [Abstract] [Full-text]
19. TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways.
    Exp Cell Res, 314(19): 3478-93. [Abstract] [Full-text]
20. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.
    Cancer, 113(10): 2638-45. [Abstract] [Full-text]
21. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
    Cancer, 113(10): 2646-54. [Abstract] [Full-text]
22. Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA.
    Br J Cancer, 99(10): 1644-50. [Abstract] [Full-text]
23. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.
    Br J Cancer, 99(10): 1572-8. [Abstract] [Full-text]
24. Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs.
    Br J Cancer, 99(10): 1623-34. [Abstract] [Full-text]
25. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
    Br J Cancer, 99(10): 1564-71. [Abstract] [Full-text]
26. Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype.
    Br J Cancer, 99(10): 1735-42. [Abstract] [Full-text]
27. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis.
    Oncogene, 27(53): 6782-9. [Abstract] [Full-text]
28. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line.
    Biochem Biophys Res Commun, 377(2): 489-94. [Abstract] [Full-text]
29. Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells.
    Biochem Biophys Res Commun, 377(2): 389-94. [Abstract] [Full-text]
30. Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation.
    Cancer Res, 68(22): 9558-65. [Abstract] [Full-text]
31. Genome-wide functional synergy between amplified and mutated genes in human breast cancer.
    Cancer Res, 68(22): 9532-40. [Abstract] [Full-text]
32. Identification of alternative splicing markers for breast cancer.
    Cancer Res, 68(22): 9525-31. [Abstract] [Full-text]
33. Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.
    Cancer Res, 68(22): 9512-8. [Abstract] [Full-text]
34. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR.
    Cancer Res, 68(22): 9469-78. [Abstract] [Full-text]
35. Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer.
    Cancer Res, 68(22): 9338-47. [Abstract] [Full-text]
36. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
    Cancer Res, 68(22): 9280-90. [Abstract] [Full-text]
37. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer.
    Cancer Res, 68(22): 9212-20. [Abstract] [Full-text]
38. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.
    Cancer Res, 68(22): 9141-6. [Abstract] [Full-text]
39. Screening mammography: does ethnicity influence patient preferences for higher recall rates given the potential for earlier detection of breast cancer?
    Radiology, 249(3): 785-91. [Abstract] [Full-text]
40. Basal cytokeratin expression in relation to biological factors in breast cancer.
    Hum Pathol, 39(12): 1744-50. [Abstract] [Full-text]
41. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer.
    Hum Pathol, 39(12): 1835-43. [Abstract] [Full-text]
42. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Hum Pathol, 39(12): 1809-15. [Abstract] [Full-text]
43. Dynamic NMR effects in breast cancer dynamic-contrast-enhanced MRI.
    Proc Natl Acad Sci U S A, 105(46): 17937-42. [Abstract] [Full-text]
44. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo.
    Proc Natl Acad Sci U S A, 105(46): 17943-8. [Abstract] [Full-text]
45. Recent trends in breast cancer among younger women in the United States.
    J Natl Cancer Inst, 100(22): 1643-8. [Abstract] [Full-text]
46. Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node.
    J Natl Cancer Inst, 100(22): 1574-80. [Abstract] [Full-text]
47. Calcium plus vitamin D supplementation and the risk of breast cancer.
    J Natl Cancer Inst, 100(22): 1581-91. [Abstract] [Full-text]
48. The natural history of invasive breast cancers detected by screening mammography.
    Arch Intern Med, 168(21): 2311-6. [Abstract] [Full-text]
49. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
    Cancer Genet Cytogenet, 187(2): 74-9. [Abstract] [Full-text]
50. Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case-control study.
    Am J Epidemiol, 168(11): 1284-91. [Abstract] [Full-text]
51. Abnormal mammography and sonography associated with foreign-body giant-cell reaction after stereotactic vacuum-assisted breast biopsy with carbon marking.
    Acta Radiol, 49(10): 1112-8. [Abstract] [Full-text]
52. Palpable breast masses with probably benign morphology at sonography: can biopsy be deferred?
    Acta Radiol, 49(10): 1104-11. [Abstract] [Full-text]
53. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
    Res Nurs Health, 31(6): 553-62. [Abstract] [Full-text]
54. Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells.
    Mol Carcinog, 47(12): 905-15. [Abstract] [Full-text]
55. Consequences of Screening in Breast Cancer (COS-BC): development of a questionnaire.
    Scand J Prim Health Care, 26(4): 251-6. [Abstract] [Full-text]
56. Sentinel lymph node molecular pathology in breast carcinoma.
    Diagn Mol Pathol, 17(4): 214-9. [Abstract] [Full-text]
57. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.
    Diagn Mol Pathol, 17(4): 220-6. [Abstract] [Full-text]
58. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
    Lancet Oncol, 9(12): 1143-8. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.